Trial Profile
Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (stage I) or with (stage II) deterioration of graft function for detecting the effectiveness of treatment with canakinumab regarding the regression of infiltrates in the graft biopsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms CanaRIa
- 19 Sep 2022 Status has been changed to completed.
- 25 Jul 2014 New trial record